Table 2.
Annualized rates of change in BPF estimates by disease phenotype with 95% CI according to PPMS vs. SPMS . (1 study year is defined as 48 weeks).
| Disease Phenotype |
Estimated rate of BPF change (95% CI) |
Estimated difference in rate of change (95% CI) |
P‐value for difference in rate of change | |
|---|---|---|---|---|
| Ibudilast | Placebo | |||
| Overall | −0.00097 | −0.00186 | 0.000890 | <0.04 |
| (−0.00157, −0.00036) | (−0.00245, −0.00126) | (0.000041, 0.001738) | ||
| PPMS 1 | −0.00088 | −0.00254 | 0.00166 | <0.01 |
| (−0.00171, 0.00005) | (−0.00334, −0.00173) | (0.00050, 0.00281) | ||
| SPMS 1 | −0.00106 | −0.00108 | 0.00002 | 0.97 |
| (−0.00193, −0.00019) | (−0.00195, −0.00022) | (−0.00121, 0.00125) | ||
1
Estimated rates of change by disease type based on model that included a three‐way interaction of time, treatment, and disease type using all modified intention‐to‐treat subjects.